Phibro(US:PAHC)2022-05-16 02:14Financial Performance - Q3 2022 - Net sales increased by $27.9 million, a 13% increase year-over-year, driven by improvements across all business segments and regions[11] - Net income increased by $5.5 million, a 45% increase year-over-year, driven by stronger volumes and selling prices[11] - Adjusted EBITDA remained comparable to the prior year's quarter at $28.0 million[11] - Adjusted net income decreased by 4% year-over-year to $13.4 million, and adjusted diluted EPS decreased by 3% year-over-year to $0.33[11] Segment Performance - Q3 2022 - Animal Health net sales increased by $14.2 million, or 11% year-over-year, to $148.6 million[15] - Mineral Nutrition net sales increased by $10.9 million, or 19% year-over-year, to $69.0 million[18] - Performance Products net sales increased by $2.8 million, or 15% year-over-year, to $22.0 million[18] Fiscal Year 2022 Guidance - The company raised full-year net sales guidance to $930-$950 million, projecting a 12-14% increase over the prior full year[9] - Adjusted EBITDA guidance was maintained at $110-$114 million[9]